392 related articles for article (PubMed ID: 7530690)
1. IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells.
Fluckiger AC; Brière F; Zurawski G; Bridon JM; Banchereau J
Immunology; 1994 Nov; 83(3):397-403. PubMed ID: 7530690
[TBL] [Abstract][Full Text] [Related]
2. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40.
Crawford DH; Catovsky D
Immunology; 1993 Sep; 80(1):40-4. PubMed ID: 7503945
[TBL] [Abstract][Full Text] [Related]
3. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C
Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693
[TBL] [Abstract][Full Text] [Related]
4. CD23 antigen regulation and signaling in chronic lymphocytic leukemia.
Fournier S; Delespesse G; Rubio M; Biron G; Sarfati M
J Clin Invest; 1992 Apr; 89(4):1312-21. PubMed ID: 1532590
[TBL] [Abstract][Full Text] [Related]
5. Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore.
Engel P; Inglés J; de la Calle O; Gallart T
Clin Exp Immunol; 1989 Apr; 76(1):61-7. PubMed ID: 2500274
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the co-stimulatory activation and progression signals.
Carlsson M; Sundström C; Bengtsson M; Tötterman TH; Rosén A; Nilsson K
Eur J Immunol; 1989 May; 19(5):913-21. PubMed ID: 2525477
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation.
Blanchard DA; Affredou MT; Vazquez A
J Immunol; 1997 Apr; 158(7):3054-61. PubMed ID: 9120257
[TBL] [Abstract][Full Text] [Related]
8. Regulation by interleukin 2 of CD23 expression of leukemic and normal B cells: comparison with interleukin 4.
Hivroz C; Vallé A; Brouet JC; Banchereau J; Grillot-Courvalin C
Eur J Immunol; 1989 Jun; 19(6):1025-30. PubMed ID: 2526738
[TBL] [Abstract][Full Text] [Related]
9. Induction of latent membrane protein expression in in vitro Epstein-Barr virus-infected leukaemic B lymphocytes by interleukin 4 and antibodies to CD40.
Crawford DH; Thomas JA; Gregory CD; Catovsky D; Chaggar K
Leukemia; 1995 May; 9(5):747-53. PubMed ID: 7539512
[TBL] [Abstract][Full Text] [Related]
10. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
11. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.
Spaner DE; Hammond C; Mena J; Shi Y
Br J Haematol; 2004 Dec; 127(5):531-42. PubMed ID: 15566356
[TBL] [Abstract][Full Text] [Related]
12. The Fc epsilon R2/CD23 antigen: a hallmark of chronic lymphocytic leukemia B cells.
Almerigogna F; Biagiotti R; Giudizi MG; Alessi A; Ricci M; Bosi A; Romagnani S
Ric Clin Lab; 1989; 19(2):129-38. PubMed ID: 2528201
[TBL] [Abstract][Full Text] [Related]
13. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.
Kater AP; Evers LM; Remmerswaal EB; Jaspers A; Oosterwijk MF; van Lier RA; van Oers MH; Eldering E
Br J Haematol; 2004 Nov; 127(4):404-15. PubMed ID: 15521917
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.
Fluckiger AC; Rossi JF; Bussel A; Bryon P; Banchereau J; Defrance T
Blood; 1992 Dec; 80(12):3173-81. PubMed ID: 1281692
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 secretion by human B lymphocytes occurs as a late event and requires additional stimulation after CD40 cross-linking.
Kindler V; Matthes T; Jeannin P; Zubler RH
Eur J Immunol; 1995 May; 25(5):1239-43. PubMed ID: 7539752
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of interleukin 4-promoted CD23 production in human B lymphocytes by transforming growth factor-beta, interferons or anti-CD19 antibody is overriden on engaging CD40.
Gordon J; Katira A; Strain AJ; Gillis S
Eur J Immunol; 1991 Aug; 21(8):1917-22. PubMed ID: 1714394
[TBL] [Abstract][Full Text] [Related]
17. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes.
Burdin N; Van Kooten C; Galibert L; Abrams JS; Wijdenes J; Banchereau J; Rousset F
J Immunol; 1995 Mar; 154(6):2533-44. PubMed ID: 7533177
[TBL] [Abstract][Full Text] [Related]
18. Activation of human B lymphocytes through CD40 and interleukin 4.
Vallé A; Zuber CE; Defrance T; Djossou O; De Rie M; Banchereau J
Eur J Immunol; 1989 Aug; 19(8):1463-7. PubMed ID: 2476318
[TBL] [Abstract][Full Text] [Related]
19. Regulatory effects of IL-4 on human B-cell response to IL-2.
Galanaud P; Karray S; Llorente L
Eur Cytokine Netw; 1990; 1(2):57-64. PubMed ID: 2102812
[TBL] [Abstract][Full Text] [Related]
20. Soluble forms of CD40 inhibit biologic responses of human B cells.
Fanslow WC; Anderson DM; Grabstein KH; Clark EA; Cosman D; Armitage RJ
J Immunol; 1992 Jul; 149(2):655-60. PubMed ID: 1378075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
